Articles

Attendees awoke to the news this morning about GlaxoSmithKline’s announcement that it will pay millions — $720 million to be exact — for Sirtris Pharmaceuticals. This is the stuff biotech CEOs dream about. And it was the buzz at many breakfast tables at this morning’s workshop, “Antibiotics: Bad Bugs – Few Drugs.”

While the economy may not be as robust as it has in recent years, there certainly was no sign of that at today’s Opening Luncheon. Jim Greenwood, our President & CEO welcomed attendees to the inaugural BIO National Venture Conference and cited these impressive stats:

The marathon may be over, but that doesn't mean there isn't plenty more activity going on here in Boston.    We're here in Cambridge, one of biotechnology's "hot-spots" for the inaugural BIO National Venture Conference meeting up with some of the newest early stage and seed stage companies seeking venture funding.  Stay tuned for more as the program gets underway...

Here at BIO, we are rethinking our online strategy and we can’t do it without you. Help us provide you with the best online information, tools and resources possible and..... Take our survey!

The Scientist, our trade publication partner for the daily newsletter at the convention, has extended their editorial submission deadline to April 30th. To submit newsworthy content, go to www.the-scientist.com/bio/index/ . Submit something today!

Super Sessions lined up for the 2008 BIO International Convention :

 

Tuesday, June 17, 2008

- Follow-on Biologics/Biosimilars

What is BIO? What is industrial biotechnology? The third wave in biotechnology.

It’s a phrase we’ve all heard a million times, but I found it interesting in the context of today’s panel discussion on diagnostic testing for the developing world.